Coronavirus vaccine maker AstraZeneca's £27.5bn ($39bn) deal to buy an American drug company is being probed by the 海角视频's competition watchdog.
The Competition and Markets Authority (CMA) said it is looking into whether AstraZeneca's acquisition of Alexion Pharmaceuticals could harm competition in the 海角视频.
The CMA has set a deadline of June 3 for comments for its so-called phase one investigation, the PA news agency reports.
AstraZeneca, which has a major base in Macclesfield, Cheshire, agreed to buy Alexion in Boston for £123 ($175) a share in December, marking the drug giant's biggest ever acquisition and a move to boost its expertise in immunology and rare diseases.
The cash-and-shares deal was approved by shareholders earlier this month.
It is a milestone for AstraZeneca - which has developed the Covid-19 jab together with Oxford University - and will diversify the group, adding to its fast-growing cancer treatment business.
AstraZeneca is hoping to complete the takeover of Alexion in the third quarter of the year.
The CMA inquiry comes just weeks after AstraZeneca's boss Pascal Soriot suffered a shareholder backlash over his pay.
Most Read
Don't miss a thing - sign up for your free North West newsletter - and follow us on LinkedIn
Email newsletters
BusinessLive is your home for business news from around the North West- and you can stay in touch with all the latest news from Greater Manchester, Liverpool City Region, Cheshire, Lancashire and Cumbria through our email alerts.
You can sign up to receive daily morning news bulletins from every region we cover and to weekly email bulletins covering key economic sectors from manufacturing to technology and enterprise. And we'll send out breaking news alerts for any stories we think you can't miss.
Visit our email preference centre to sign up to all the latest news from BusinessLive.
For all the latest stories, views, polls and more - and the news as it breaks - .
Nearly 40% of investors voted against plans to boost the maximum payout for the chief executive from 550% to 650% of his £1.3m salary.
The group pledged to talk to investors in a bid to understand their concerns after its executive pay plans narrowly passed at the annual general meeting.
The pharmaceutical firm is, meanwhile, facing political pressure over its coronavirus vaccine, with a legal battle launched by the European Union over a supply row, while there have also been blood clot concerns over the jab.
Protesters also staged a demonstration at its Cambridge base earlier this month, calling on the group to share its Covid-19 vaccine technology.